Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Abstract
Recent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors including hepatocellular carcinoma (HCC). Overexpression of MET receptor tyrosine kinase is common in HCC; however, MET inhibitors are effective only when MET is in an active form, making patient stratification difficult. Specific MET-targeting CAR-T cells hold the promise of targeting HCC with MET overexpression regardless of signaling pathway activity.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2023
- Source ID
- 10.1186/s12967-023-04521-9
Entities
People
- Anna Musket
- Anna Qin
- Francesco M. Marincola
- Giedre Krenciute
- Joseph J Lee
- Mingyao Ying
- Phillip R. Musich
- Qian Xie
- Yuan Qin
- Zhi Q Yao
Organizations
- Gilead Sciences
- United States Department of Defense